New obesity pill shows promise in early trial
NCT ID NCT06841445
First seen Apr 14, 2026
Summary
This completed Phase 2 study tested an experimental pill called HRS9531 in 166 adults with obesity. Participants took either the drug or a placebo daily for 26 weeks. The main goal was to see how much weight they lost compared to those on placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Drum Tower hospital
Nanjing, Jiangsu, 210008, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS9531 tablet
What this could lead to
If successful, this could lead to a new oral medication for chronic weight management in people with obesity.
What could go wrong
This is a Phase 2 trial with only 166 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.